Eyenovia Q3 2024 net loss $7.9M; advances MicroPine Phase 3 and launches clobetasol

HYPERION DEFI, INC.

2024-Q3 EPS reported -$0.53 revenue$29,243

Net loss of $7.9M ($0.11/share) vs $7.3M ($0.18/share) in Q3 2023; SG&A up 27% to $3.7M.
Cash & equivalents $7.2M at Sept 30, 2024; evaluating long-term financing options.
Phase 3 CHAPERONE (MicroPine) interim analysis planned this quarter; myopia market >$3B annually.
U.S. launch of clobetasol propionate 0.05% for post-surgical ocular inflammation/pain.
Mydcombi shipped to 230 new offices since April; appointed Andrew Jones as CFO; raised $10.7M net.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.